Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;8(1):e53411.
doi: 10.1371/journal.pone.0053411. Epub 2013 Jan 7.

Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai

Yunjuan Gu  1 , Chunfang Wang, Ying Zheng, Xuhong Hou, Yifei Mo, Weihui Yu, Lei Zhang, Cheng Hu, Hairong Nan, Lei Chen, Jie Li, Yuxiang Liu, Zhezhou Huang, Ming Han, Yuqian Bao, Weijian Zhong, Weiping Jia
Affiliations

Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai

Yunjuan Gu et al. PLoS One. 2013.

Abstract

Aim: The aim was to investigate the association between human insulin and cancer incidence and mortality in Chinese patients with type 2 diabetes.

Methods: We recruited 8,774 insulin-naïve diabetes patients from the Shanghai Diabetes Registry (SDR). The follow-up rate was 85.4%. All subjects were divided into the insulin use cohort (n = 3,639) and the non-insulin use cohort (n = 5,135). The primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. Cox proportional hazards model was used to estimate the relative risk (RR) of cancer and mortality.

Results: We observed 98 cancer events in the insulin use cohort and 170 in the non-insulin use cohort. Cancer incidence rates were 78.6 and 74.3 per 10,000 patients per year in the insulin users and the non-insulin users, respectively. No significant difference in cancer risk was observed between the two cohorts (adjusted RR = 1.20, 95% CI 0.89-1.62, P = 0.228). Regarding site-specific cancers, only the risk of liver cancer was significantly higher in the insulin users compared to that in the non-insulin users (adjusted RR = 2.84, 95% CI 1.12-7.17, P = 0.028). The risks of overall mortality (adjusted RR = 1.89, 95% CI 1.47-2.43, P<0.0001) and death from cancer (adjusted RR = 2.16, 95% CI 1.39-3.35, P = 0.001) were all significantly higher in the insulin users than in the non-insulin users.

Conclusion: There was no excess risk of overall cancer in patients with type 2 diabetes who were treated with human insulin. However, a significantly higher risk of liver cancer was found in these patients. Moreover, insulin users showed higher risks of overall and cancer mortality. Considering that individuals treated with insulin were more likely to be advanced diabetic patients, caution should be used in interpreting these results.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow chart of the type 2 diabetic patients in the study.
Figure 2
Figure 2. Kaplan–Meier curves of the proportion of participants with events over time.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47: 87–95. - PubMed
    1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207–221. - PubMed
    1. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254–258. - PubMed
    1. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52: 1745–1754. - PubMed
    1. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, et al. (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33: 1997–2003. - PMC - PubMed

Publication types

MeSH terms